Better Therapeutics, Inc. (BTTX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 23.84 Million USD | 67.45% |
| 2021 | 14.23 Million USD | 8.31% |
| 2020 | 13.14 Million USD | 139.61% |
| 2019 | 5.48 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 22.64 Million USD | -5.04% |
| 2023 Q2 | 22.39 Million USD | -1.1% |
| 2023 Q3 | 20.65 Million USD | -7.74% |
| 2022 Q3 | 20.96 Million USD | 10.08% |
| 2022 Q2 | 19.04 Million USD | 48.06% |
| 2022 Q1 | 12.86 Million USD | -9.64% |
| 2022 FY | 23.84 Million USD | 67.45% |
| 2022 Q4 | 23.84 Million USD | 13.7% |
| 2021 FY | 14.23 Million USD | 8.31% |
| 2021 Q4 | 14.23 Million USD | 530.82% |
| 2021 Q3 | 2.25 Million USD | -92.58% |
| 2021 Q2 | 30.4 Million USD | 1361.19% |
| 2021 Q1 | 2.08 Million USD | 15729.84% |
| 2020 Q4 | 13.14 Thousand USD | 0.0% |
| 2020 FY | 13.14 Million USD | 139.61% |
| 2020 Q1 | - USD | 0.0% |
| 2019 FY | 5.48 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -394.138% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -903.451% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 38.752% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 82.024% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -757.935% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -187.808% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -139.037% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 9.48% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 24.985% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 65.662% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | -200.066% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 50.444% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 84.845% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -580.043% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -11.988% |
| Molecular Templates, Inc. | 31.17 Million USD | 23.512% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -90.509% |
| NexImmune, Inc. | 5.08 Million USD | -368.94% |
| Orgenesis Inc. | 35.53 Million USD | 32.906% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -44.392% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -8849.229% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -938.717% |
| Scopus BioPharma Inc. | 7.45 Million USD | -219.836% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 95.179% |
| Statera Biopharma, Inc. | 22.67 Million USD | -5.14% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -118.453% |
| Trevena, Inc. | 48.26 Million USD | 50.599% |
| Vaxxinity, Inc. | 30.94 Million USD | 22.951% |
| Vaccinex, Inc. | 5.94 Million USD | -301.245% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -1111.276% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 37.868% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -763.353% |